한국인 심혈관질환의 일차 예방을 위한 Amlodipine/Atorvastatin 단일 복합제의 비용 효과 분석
Cost-Effectiveness of Single-Pill Combination Therapy of Amlodipine/Atorvastatin Compared with Concurrent Two-Pill Therapy in Patients with Hypertension in Korea
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Objectives: Single-pill combination therapy may be more effective compared with two pill approach in hypertensive patients requiring concomitant statin therapy. We investigated the cost-effectiveness of single-pill amlodipine/atorvastatin (SP) therapy compared with two-pill co-administration (TP) therapy for prevention of cardiovascular disease (CVD) with consideration to adherence in patients with hypertension using simulation model. Methods: Cohort simulation was performed with 1000 hypertensive patients at an increased risk of CVD or with concomitant dyslipidemia. The efficacy was defined as the number of CVD prevention, which depends on differences in patients’ adherence to each alternative. ‘Adherence’ was defined as compliance to medication over 80% on proportional day covered and ‘non-adherence’ for the remaining. The number of cardiovascular event after TP treatment was based on the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) trial. The proportion of the adherent patient and the cardiovascular outcome differences in adherence level were searched through systematic review. The annual costs of medicine were included according to the adherence levels of each alternative. Average cost-effectiveness ratio (ACER) was calculated as the cost per CVD event prevented in the cohort. All costs were described in 1000 Korean won (KRW). Results: The number of CVD prevention in SP approach was higher than in TP approach by approximately 1–4 cases. Total annual medication cost with SP approach was 209719–225164 KRW which was lesser than the cost in TP approach, 261893–281993 KRW. ACERs in SP approach were lower than those in TP approach (214–231 KRW vs. 268–298 KRW per prevented CVD event, respectively). SP approach reduced medication cost by around 20% per cardiovascular prevention case than TP approach. Conclusion: SP approach is cost effective compared with TP approach in hypertensive patients at risk of cardiovascular event or those with concomitant dyslipidemia for CVD prevention.
Abstract
Objectives: Single-pill combination therapy may be more effective compared with two pill approach in hypertensive patients requiring concomitant statin therapy. We investigated the cost-effectiveness of single-pill amlodipine/atorvastatin (SP) therapy compared with two-pill co-administration (TP) therapy for prevention of cardiovascular disease (CVD) with consideration to adherence in patients with hypertension using simulation model. Methods: Cohort simulation was performed with 1000 hypertensive patients at an increased risk of CVD or with concomitant dyslipidemia. The efficacy was defined as the number of CVD prevention, which depends on differences in patients’ adherence to each alternative. ‘Adherence’ was defined as compliance to medication over 80% on proportional day covered and ‘non-adherence’ for the remaining. The number of cardiovascular event after TP treatment was based on the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) trial. The proportion of the adherent patient and the cardiovascular outcome differences in adherence level were searched through systematic review. The annual costs of medicine were included according to the adherence levels of each alternative. Average cost-effectiveness ratio (ACER) was calculated as the cost per CVD event prevented in the cohort. All costs were described in 1000 Korean won (KRW). Results: The number of CVD prevention in SP approach was higher than in TP approach by approximately 1–4 cases. Total annual medication cost with SP approach was 209719–225164 KRW which was lesser than the cost in TP approach, 261893–281993 KRW. ACERs in SP approach were lower than those in TP approach (214–231 KRW vs. 268–298 KRW per prevented CVD event, respectively). SP approach reduced medication cost by around 20% per cardiovascular prevention case than TP approach. Conclusion: SP approach is cost effective compared with TP approach in hypertensive patients at risk of cardiovascular event or those with concomitant dyslipidemia for CVD prevention.
참고문헌 (21)
- Asia Pacific Cohort Studies Collaboration, "Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region", Circulation, 112, pp.3384~3390 (2005)
- Mancia G, "Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)", Eur Heart J, 28, pp.1462~1536 (2007)
- Johnson ML, "Therapeutic goal attainment in patients with hypertension and dyslipidemia", Med Care, 44, pp.39~46 (2006)
- Cowie MR, "Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine", atorvastatin single-pill therapy, 2005, pp.59, 839~846
- Cramer JA, "Partial medication compliance: the enigma in poor medical outcomes", Am J Managed Care, 1, pp.167~174 (1995)
- Osterberg L, "Adherence to medication", N Engl J Med, 353, pp.487~497 (2005)
- Chapman RH, "Predictors of adherence with antihypertensive and lipid-lowering therapy", Arch Intern Med, 165, pp.1147~1152 (2005)
- Dezii CM, "A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension", Manag Care, 9(9 Suppl), pp.2~6 (2000)
- Dezii CM, "Medication noncompliance: what is the problem?", Manag Care, 9(9 Suppl), pp.7~12 (2009)
- Simpson SH, "A meta-analysis of the association between adherence to drug therapy and mortality", BMJ, 333, pp.15~ (2006)
- Chung M, "Bioavailability of amlodipine besylate", atorvastatin calcium combination tablet, 2006, pp.46, 1030~1037
- Patel BV, "Adherence with single-pill amlodipine", atorvastatin vs a two-pill regimen, 2008, pp.4, 673~681
- Sever PS, "Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension", J Hypertens, 27, pp.947~954 (2009)
- Chapman RH, "Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees", BMC Cardiovasc Disord, 10, pp.29~ (2010)
- Bouchard MH, "Impact of adherence to statins on coronary artery disease in primary prevention", Br J Clin Pharmacol, 63, pp.698~708 (2007)
- Ruokoniemi P, "Statin adherence and the risk of major coronary events in patients with diabetes: a nested case-control study", Br J Clin Pharmacol, 71, pp.766~776 (2011)
- Dragomir A, "Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs", Med Care, 48, pp.418~425 (2010)
- Wu PH, "Relationship of blood pressure control and hospitalization risk to medication adherence among patients with hypertension in Taiwan", Am J Hypertens, 23, pp.155~160 (2010)
- Wald NJ, "A strategy to reduce cardiovascular disease by more than 80%", BMJ, 326, pp.1419~ (2003)
- Chapman RH, "The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications", Value Health, 13, pp.685~694 (2010)
- Liew D, "Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea", Clin Ther, 31, pp.2189~2203 (2009)